Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Bioequivalence Study of CJ-30060 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03757390
Recruitment Status : Recruiting
First Posted : November 28, 2018
Last Update Posted : November 28, 2018
Sponsor:
Information provided by (Responsible Party):
CJ HealthCare Corporation

Brief Summary:
To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: Exforge® tab 5/160mg, Crestor® tab 10mg Drug: CJ-30060 5/160/10mg Phase 1

Detailed Description:
The purpose of this study is to compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CJ-30060 in Healthy Subjects
Actual Study Start Date : November 9, 2018
Estimated Primary Completion Date : December 14, 2018
Estimated Study Completion Date : December 14, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Sequence 1
  • period 1: receive Exforge® tab 5/160mg, Crestor® tab 10mg
  • period 2: receive CJ-30060 5/160/10mg
Drug: Exforge® tab 5/160mg, Crestor® tab 10mg
co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg

Drug: CJ-30060 5/160/10mg
Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg

Experimental: Sequence 2
  • period 1: receive CJ-30060 5/160/10mg
  • period 2: receive Exforge® tab 5/160mg, Crestor® tab 10mg
Drug: Exforge® tab 5/160mg, Crestor® tab 10mg
co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg

Drug: CJ-30060 5/160/10mg
Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg




Primary Outcome Measures :
  1. Cmax of amlodipine [ Time Frame: Up to 144 hours post-dose ]
  2. Cmax of valsartan [ Time Frame: Up to 48 hours post-dose ]
  3. Cmax of rosuvastatin [ Time Frame: Up to 72 hours post-dose ]
  4. AUClast of amlodipine [ Time Frame: Up to 144 hours post-dose ]
  5. AUClast of valsartan [ Time Frame: Up to 48 hours post-dose ]
  6. AUClast of rosuvastatin [ Time Frame: Up to 72 hours post-dose ]

Secondary Outcome Measures :
  1. AUCinf of amlodipine, valsartan, rosuvastatin [ Time Frame: Up to 144 hours post-dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers aged 20 to 45 years at screening
  • BMI: 18~29.9kg/㎡
  • Body weight ≥50kg
  • Subjects who decided to participate in the study and signed informed consent form voluntarily after receiving detailed explanation of the study and fully understanding

Exclusion Criteria:

  • Subjects who had a medical history of severe cardiovascular, respiratory, hepatobiliary, renal, hematological, gastrointestinal, endocrinological, immunological, dermatological or neuropsychological disease
  • Subjects who have symptoms of an acute disease within 28days before first administration
  • Subjects who have clinically significant active, chronic disease
  • Subjects who fall under the criteria below in laboratory test

    • AST/ALT > UNL (upper normal limit) × 2
    • Total bilirubin > UNL × 1.5
    • CrCL < 50mL/min
    • CPK > UNL × 2.5
  • Subjects with clinically significant low blood pressure at screening test(systolic blood presure is less than 100mmHg or diastolic blood pressure is less than 60mmHg)
  • Subjects with any positive reaction in HBsAg, anti-HCV Ab, anti HIV Ab, VDRL tests

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03757390


Contacts
Layout table for location contacts
Contact: Hyo-Sook Seo 82-2-6477-0262 hs.seo1@cj.net
Contact: Min-ja Kang 82-2-6477-0260 minja.kang@cj.net

Locations
Layout table for location information
Korea, Republic of
Korea University Anam Hospital Recruiting
Seoul, Korea, Republic of
Sponsors and Collaborators
CJ HealthCare Corporation
Investigators
Layout table for investigator information
Principal Investigator: Ji Young Park, PhD Korea University Anam Hospital

Layout table for additonal information
Responsible Party: CJ HealthCare Corporation
ClinicalTrials.gov Identifier: NCT03757390    
Other Study ID Numbers: CJ_EXR_104
First Posted: November 28, 2018    Key Record Dates
Last Update Posted: November 28, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Amlodipine, Valsartan Drug Combination
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors
Antihypertensive Agents